Jacques Cadranel mainly investigates Internal medicine, Pathology, Surgery, Lung cancer and Gastroenterology. His Internal medicine research is multidisciplinary, relying on both Aspergillosis, Immunology and Oncology. Jacques Cadranel has included themes like Docetaxel and Bioinformatics in his Oncology study.
The study incorporates disciplines such as Dermatology, Pleural effusion, Lung and Tumor-infiltrating lymphocytes in addition to Pathology. His studies in Surgery integrate themes in fields like Adverse effect, Incidence, Cohort and Pneumonia. His work carried out in the field of Lung cancer brings together such families of science as Cancer, Anal cancer, Adenocarcinoma, Carcinoma and Risk factor.
Jacques Cadranel mostly deals with Internal medicine, Oncology, Lung cancer, Pathology and Lung. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Surgery. His research integrates issues of KRAS and Epidermal growth factor receptor in his study of Oncology.
His Lung cancer research includes themes of Cancer, Performance status and Cancer research. In his research on the topic of Pathology, Immunology is strongly related with Bronchoalveolar lavage. His specific area of interest is Lung, where Jacques Cadranel studies Respiratory disease.
His primary scientific interests are in Internal medicine, Oncology, Lung cancer, Non small cell and Cancer research. His research related to Cancer, Idiopathic pulmonary fibrosis, Chemotherapy, Lung and Cohort might be considered part of Internal medicine. The concepts of his Oncology study are interwoven with issues in Confidence interval, Hazard ratio, Treatment outcome and KRAS.
His Lung cancer research is multidisciplinary, incorporating elements of Prospective cohort study, Performance status and Adenocarcinoma. The various areas that Jacques Cadranel examines in his Non small cell study include Molecular biology, Response Duration and Immunotherapy. His work focuses on many connections between Cancer research and other disciplines, such as Afatinib, that overlap with his field of interest in Treatment options and ErbB.
Internal medicine, Oncology, Cancer, Lung cancer and Non small cell are his primary areas of study. His work in Cohort study, Chemotherapy, Cohort, Mortality rate and Intensive care unit are all subfields of Internal medicine research. His biological study spans a wide range of topics, including Mucinous Adenocarcinomas, Lung and Treatment outcome.
Jacques Cadranel combines subjects such as Fusion gene, Disease and Retrospective cohort study with his study of Cancer. His work in the fields of Osimertinib overlaps with other areas such as In patient. His Non small cell research integrates issues from Treatment of lung cancer, Therapeutic algorithm, Confidence interval and Immunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen.
Lancet Oncology (2012)
Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures
Marie-Caroline Dieu-Nosjean;Martine Antoine;Claire Danel;Didier Heudes.
Journal of Clinical Oncology (2008)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre.
The Lancet (2016)
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study
Marguerite Guiguet;François Boué;Jacques Cadranel;Jean-Marie Lang.
Lancet Oncology (2009)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning.
Clinical Microbiology and Infection (2018)
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
Aryeh Fischer;Katerina M. Antoniou;Kevin K. Brown;Jacques Cadranel.
European Respiratory Journal (2015)
Primary pulmonary lymphoma
J Cadranel;M Wislez;M Antoine.
European Respiratory Journal (2002)
Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients.
Eric Oksenhendler;Monica Duarte;Jean Soulier;Patrice Cacoub.
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
David W. Denning;Jacques Cadranel;Catherine Beigelman-Aubry;Florence Ader.
European Respiratory Journal (2016)
Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected Patients
Magid Herida;Murielle Mary-Krause;Régis Kaphan;Jacques Cadranel.
Journal of Clinical Oncology (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: